Orally administered supplementation of GLN was shown to prevent breast tumor growth by inhibiting production of the antioxidant glutathione, activating p53 signaling, and inhibiting PI3 K/Akt signaling [14, 15]. The gene discussed is TP53; the disease is breast neoplasm.